DK2666475T3 - Terapeutisk middel til skaldethed - Google Patents

Terapeutisk middel til skaldethed

Info

Publication number
DK2666475T3
DK2666475T3 DK12736336.4T DK12736336T DK2666475T3 DK 2666475 T3 DK2666475 T3 DK 2666475T3 DK 12736336 T DK12736336 T DK 12736336T DK 2666475 T3 DK2666475 T3 DK 2666475T3
Authority
DK
Denmark
Prior art keywords
boldness
therapeutic agent
therapeutic
agent
Prior art date
Application number
DK12736336.4T
Other languages
English (en)
Inventor
Kyoko Endo
Original Assignee
Igisu Co Ltd
Endo Yori
Kyoko Endo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igisu Co Ltd, Endo Yori, Kyoko Endo filed Critical Igisu Co Ltd
Application granted granted Critical
Publication of DK2666475T3 publication Critical patent/DK2666475T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK12736336.4T 2011-01-21 2012-01-20 Terapeutisk middel til skaldethed DK2666475T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011011437 2011-01-21
PCT/JP2012/051272 WO2012099258A1 (ja) 2011-01-21 2012-01-20 脱毛症治療剤

Publications (1)

Publication Number Publication Date
DK2666475T3 true DK2666475T3 (da) 2017-11-20

Family

ID=46515875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12736336.4T DK2666475T3 (da) 2011-01-21 2012-01-20 Terapeutisk middel til skaldethed

Country Status (14)

Country Link
US (4) US20120238498A1 (da)
EP (2) EP3269382A1 (da)
JP (1) JP5261620B2 (da)
KR (1) KR101954869B1 (da)
CN (2) CN103547282A (da)
AU (2) AU2012207816B2 (da)
BR (1) BR112013018679B1 (da)
CA (1) CA2825382C (da)
DK (1) DK2666475T3 (da)
ES (1) ES2647680T3 (da)
HU (1) HUE035584T2 (da)
MX (1) MX353295B (da)
TW (2) TWI619505B (da)
WO (1) WO2012099258A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457581B1 (en) 2009-07-23 2014-01-08 Igisu Co., Ltd. Composition comprising cnp or bnp for external preparation for skin for the treatment of dermatitis
BR112013018679B1 (pt) 2011-01-21 2022-04-12 Igisu Co. Ltd. Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c
WO2016175559A2 (ko) * 2015-04-28 2016-11-03 (주) 메드빌 지모와 두릅의 복합 추출물을 함유하는 탈모 방지 및 발모 개선용 조성물
TW201708247A (zh) 2015-05-29 2017-03-01 Igisu Co Ltd 環狀胜肽及含該環狀胜肽之藥物、外用劑及化粧品
EP3689897A1 (en) * 2015-07-31 2020-08-05 Igisu Co., Ltd. A cnp cyclic peptide and a medicament, external preparation and cosmetic containing the cyclic peptide
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
EA039431B1 (ru) * 2016-03-18 2022-01-26 Кареджен Ко., Лтд. Конъюгат финастерида с пептидом
US11274126B2 (en) 2016-03-21 2022-03-15 University Of Rhode Island Board Of Trustees pH-sensitive cyclic peptides
WO2018034622A1 (en) * 2016-08-18 2018-02-22 National University Of Singapore Peptides with vasodilatory and/or diuretic functions
KR101948238B1 (ko) * 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
US9956158B2 (en) * 2016-09-08 2018-05-01 Synergistic Therapeutics, Llc Topical hair growth formulation
CN108424446A (zh) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 新的重组人心房利钠肽突变体的制备及其应用
WO2019168348A1 (ko) * 2018-02-28 2019-09-06 주식회사 마더스제약 탈모 치료 및 발모 촉진용 조성물
CN109011138A (zh) * 2018-05-07 2018-12-18 北京全贵医疗科技有限公司 基于头部图像的头部理疗方法及装置
WO2020123312A1 (en) 2018-12-09 2020-06-18 Weinberg Assa Method to prevent and treat macular degeneration by vasodilators
WO2020154304A1 (en) * 2019-01-24 2020-07-30 Weinberg Assa Method to prevent and treat alopecia by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers
JP7575722B2 (ja) * 2019-10-28 2024-10-30 大正製薬株式会社 外用医薬組成物
US20250276999A1 (en) * 2022-04-19 2025-09-04 Trustees Of Tufts College Peptides for promoting hair follicle neogenesis, and prevention/mitigation of untoward effects of radiation treatment
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도
KR102890438B1 (ko) * 2023-10-16 2025-11-25 (주)뉴트리 탈모 증상 완화능을 갖는 두피 유래 펩타이드

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804650A (en) 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
US5047397A (en) 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Cnp類似体ペプチド
JPH05207891A (ja) 1991-03-08 1993-08-20 Shionogi & Co Ltd 脳性ナトリウム利尿ペプチドの製造方法
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
JP3799465B2 (ja) 1998-09-28 2006-07-19 参天製薬株式会社 ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US7887842B2 (en) * 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
CA2528883A1 (en) 2003-06-13 2004-12-23 Daiichi Asubio Pharma Co., Ltd. Pharmaceutical compositions for preventing or treating th1-mediated immune diseases
KR100509446B1 (ko) 2003-06-19 2005-08-22 세메스 주식회사 반도체 제조 공정에서 사용되는 약액 공급 장치
CN101208353B (zh) 2003-06-20 2011-12-14 梅约医学教育与研究基金会 脑利尿钠肽的同种型
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
AU2005207886A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
JP2007525213A (ja) 2004-01-27 2007-09-06 コンピュゲン ユーエスエイ,インク. 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
MX2007001667A (es) 2004-08-11 2007-10-02 Johnson & Johnson Aparato y metodo para el suministro transdermico de peptidos natriureticos.
EP1810716A1 (de) 2005-12-23 2007-07-25 Deutsches Zentrum für Luft- und Raumfahrt e.V. Verfahren zur Bräunung der Haut
US7196223B2 (en) * 2005-05-03 2007-03-27 Solutia, Inc. Higher alcohols for solvents in amine production
JP3830960B1 (ja) 2005-08-12 2006-10-11 建仁 河乃 育毛物質
US8324162B2 (en) 2006-08-08 2012-12-04 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
JPWO2008032450A1 (ja) 2006-09-15 2010-01-21 国立大学法人京都大学 脂肪肝の予防剤および/または治療剤
KR100842392B1 (ko) 2006-10-10 2008-07-01 주식회사 일진글로벌 토크를 측정할 수 있는 구동휠시스템
JP2008140125A (ja) 2006-12-01 2008-06-19 Rakuten Inc サービス予約システム、予約登録装置、参加者募集方法及び参加者募集処理プログラム
US20120034183A1 (en) 2006-12-19 2012-02-09 Michael Cohen Compositions and methods for growing embryonic stem cells
JP5010913B2 (ja) * 2006-12-31 2012-08-29 寿子 小出 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2010168283A (ja) 2007-04-24 2010-08-05 Yamaguchi Univ ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤
JP5207316B2 (ja) 2007-05-10 2013-06-12 国立大学法人名古屋大学 腹膜線維化抑制用医薬組成物
JP2009013122A (ja) * 2007-07-06 2009-01-22 Masaru Okura 育毛剤
KR20100057063A (ko) 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2010078325A2 (en) * 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
EP2457581B1 (en) * 2009-07-23 2014-01-08 Igisu Co., Ltd. Composition comprising cnp or bnp for external preparation for skin for the treatment of dermatitis
WO2011024973A1 (ja) * 2009-08-27 2011-03-03 株式会社 イギス 鼻炎治療剤
BR112013018679B1 (pt) 2011-01-21 2022-04-12 Igisu Co. Ltd. Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c

Also Published As

Publication number Publication date
EP2666475A8 (en) 2014-03-19
EP3269382A1 (en) 2018-01-17
AU2012207816A1 (en) 2013-08-22
AU2012207816B2 (en) 2017-03-09
HUE035584T2 (en) 2018-05-28
BR112013018679B1 (pt) 2022-04-12
TW201811360A (zh) 2018-04-01
US11571464B2 (en) 2023-02-07
US20170065680A1 (en) 2017-03-09
CN103547282A (zh) 2014-01-29
US20140315810A1 (en) 2014-10-23
CA2825382A1 (en) 2012-07-26
EP2666475A1 (en) 2013-11-27
MX353295B (es) 2018-01-08
KR20140041437A (ko) 2014-04-04
TW201244734A (en) 2012-11-16
US20120238498A1 (en) 2012-09-20
MX2013008422A (es) 2013-10-03
US20180133289A1 (en) 2018-05-17
TWI619505B (zh) 2018-04-01
US9480728B2 (en) 2016-11-01
WO2012099258A1 (ja) 2012-07-26
JP5261620B2 (ja) 2013-08-14
JPWO2012099258A1 (ja) 2014-06-30
ES2647680T3 (es) 2017-12-26
CN110801514A (zh) 2020-02-18
CA2825382C (en) 2020-07-28
KR101954869B1 (ko) 2019-05-30
AU2017203793A1 (en) 2017-06-22
EP2666475B1 (en) 2017-08-16
EP2666475A4 (en) 2014-12-31
BR112013018679A2 (pt) 2016-10-18
US9808511B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
CO6801645A2 (es) Nuevos inmunoconjugados
EP2782540A4 (en) CHAIR WITH ROLLERS
DK2694038T3 (da) Farmaceutisk sammensætning
EP2663304A4 (en) COMBINATION THERAPY
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112014002399A2 (pt) conjunto
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2726095A4 (en) COMBINATION THERAPY
BR112014000879A2 (pt) deflegmador
FI20115876A0 (fi) Yhdistelmähoito
CO6960543A2 (es) 2-tiopirimidinonas
DK2849760T3 (da) Fremgangsmåder til oligonukleotid-chelatkompleks
DK3141251T3 (da) Koloskopi - forberedelse
EP2860233A4 (en) PUNCTURE CLOSURE MEANS
BR112014009319A2 (pt) compostos farmacêuticos
IL229081A0 (en) Isoxazolines as therapeutic agents
CO6880064A2 (es) Métodos terapéuticos
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
FI20115640A0 (fi) Yhdistelmähoito
DK2476953T3 (da) Fluidbedkedel
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung
EP2687212A4 (en) DRUG